Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

Cognitive impairment and increased Aβ levels induced by paraquat exposure are attenuated by enhanced removal of mitochondrial H(2)O(2).

Chen L, Yoo SE, Na R, Liu Y, Ran Q.

Neurobiol Aging. 2012 Feb;33(2):432.e15-26. doi: 10.1016/j.neurobiolaging.2011.01.008. Epub 2011 Mar 22.

PMID:
21429624
2.

NLRP3 inflammasome activation by mitochondrial reactive oxygen species plays a key role in long-term cognitive impairment induced by paraquat exposure.

Chen L, Na R, Boldt E, Ran Q.

Neurobiol Aging. 2015 Sep;36(9):2533-43. doi: 10.1016/j.neurobiolaging.2015.05.018. Epub 2015 Jun 6.

PMID:
26119225
3.

Mitochondrial amyloid-beta levels are associated with the extent of mitochondrial dysfunction in different brain regions and the degree of cognitive impairment in Alzheimer's transgenic mice.

Dragicevic N, Mamcarz M, Zhu Y, Buzzeo R, Tan J, Arendash GW, Bradshaw PC.

J Alzheimers Dis. 2010;20 Suppl 2:S535-50. doi: 10.3233/JAD-2010-100342.

PMID:
20463404
4.

Enhanced defense against mitochondrial hydrogen peroxide attenuates age-associated cognition decline.

Chen L, Na R, Ran Q.

Neurobiol Aging. 2014 Nov;35(11):2552-61. doi: 10.1016/j.neurobiolaging.2014.05.007. Epub 2014 May 10.

PMID:
24906890
5.

Amyloid beta-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis.

Keil U, Bonert A, Marques CA, Scherping I, Weyermann J, Strosznajder JB, Müller-Spahn F, Haass C, Czech C, Pradier L, Müller WE, Eckert A.

J Biol Chem. 2004 Nov 26;279(48):50310-20. Epub 2004 Sep 14.

8.

Long-term electromagnetic field treatment enhances brain mitochondrial function of both Alzheimer's transgenic mice and normal mice: a mechanism for electromagnetic field-induced cognitive benefit?

Dragicevic N, Bradshaw PC, Mamcarz M, Lin X, Wang L, Cao C, Arendash GW.

Neuroscience. 2011 Jun 30;185:135-49. doi: 10.1016/j.neuroscience.2011.04.012. Epub 2011 Apr 13.

PMID:
21514369
9.

Soluble Aβ levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease.

Zhang W, Hao J, Liu R, Zhang Z, Lei G, Su C, Miao J, Li Z.

Behav Brain Res. 2011 Sep 23;222(2):342-50. doi: 10.1016/j.bbr.2011.03.072. Epub 2011 Apr 14.

PMID:
21513747
10.

Twofold overexpression of human beta-amyloid precursor proteins in transgenic mice does not affect the neuromotor, cognitive, or neurodegenerative sequelae following experimental brain injury.

Murai H, Pierce JE, Raghupathi R, Smith DH, Saatman KE, Trojanowski JQ, Lee VM, Loring JF, Eckman C, Younkin S, McIntosh TK.

J Comp Neurol. 1998 Mar 23;392(4):428-38.

PMID:
9514508
11.

4-O-methylhonokiol attenuated memory impairment through modulation of oxidative damage of enzymes involving amyloid-β generation and accumulation in a mouse model of Alzheimer's disease.

Choi IS, Lee YJ, Choi DY, Lee YK, Lee YH, Kim KH, Kim YH, Jeon YH, Kim EH, Han SB, Jung JK, Yun YP, Oh KW, Hwang DY, Hong JT.

J Alzheimers Dis. 2011;27(1):127-41. doi: 10.3233/JAD-2011-110545.

PMID:
21799245
12.

Melatonin treatment restores mitochondrial function in Alzheimer's mice: a mitochondrial protective role of melatonin membrane receptor signaling.

Dragicevic N, Copes N, O'Neal-Moffitt G, Jin J, Buzzeo R, Mamcarz M, Tan J, Cao C, Olcese JM, Arendash GW, Bradshaw PC.

J Pineal Res. 2011 Aug;51(1):75-86. doi: 10.1111/j.1600-079X.2011.00864.x. Epub 2011 Mar 1.

PMID:
21355879
13.

Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease.

Olcese JM, Cao C, Mori T, Mamcarz MB, Maxwell A, Runfeldt MJ, Wang L, Zhang C, Lin X, Zhang G, Arendash GW.

J Pineal Res. 2009 Aug;47(1):82-96. doi: 10.1111/j.1600-079X.2009.00692.x. Epub 2009 Jun 17.

PMID:
19538338
14.

Amyloid precursor protein processing and retinal pathology in mouse models of Alzheimer's disease.

Dutescu RM, Li QX, Crowston J, Masters CL, Baird PN, Culvenor JG.

Graefes Arch Clin Exp Ophthalmol. 2009 Sep;247(9):1213-21. doi: 10.1007/s00417-009-1060-3. Epub 2009 Mar 7.

PMID:
19271231
15.

Soluble beta-amyloid leads to mitochondrial defects in amyloid precursor protein and tau transgenic mice.

Eckert A, Hauptmann S, Scherping I, Rhein V, Müller-Spahn F, Götz J, Müller WE.

Neurodegener Dis. 2008;5(3-4):157-9. doi: 10.1159/000113689. Epub 2008 Mar 6.

PMID:
18322377
16.

Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice.

Trinchese F, Liu S, Battaglia F, Walter S, Mathews PM, Arancio O.

Ann Neurol. 2004 Jun;55(6):801-14.

PMID:
15174014
17.

Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1.

Ohno M, Chang L, Tseng W, Oakley H, Citron M, Klein WL, Vassar R, Disterhoft JF.

Eur J Neurosci. 2006 Jan;23(1):251-60.

PMID:
16420434
18.

Lifelong immunization with human beta-amyloid (1-42) protects Alzheimer's transgenic mice against cognitive impairment throughout aging.

Jensen MT, Mottin MD, Cracchiolo JR, Leighty RE, Arendash GW.

Neuroscience. 2005;130(3):667-84.

PMID:
15590151
19.

Powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice.

Pan X, Gong N, Zhao J, Yu Z, Gu F, Chen J, Sun X, Zhao L, Yu M, Xu Z, Dong W, Qin Y, Fei G, Zhong C, Xu TL.

Brain. 2010 May;133(Pt 5):1342-51. doi: 10.1093/brain/awq069. Epub 2010 Apr 12.

PMID:
20385653
20.

Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice.

Lazarov O, Robinson J, Tang YP, Hairston IS, Korade-Mirnics Z, Lee VM, Hersh LB, Sapolsky RM, Mirnics K, Sisodia SS.

Cell. 2005 Mar 11;120(5):701-13.

Supplemental Content

Support Center